SELLAS Life Sciences Group, Inc.
News
SELLAS Life Sciences Group (NASDAQ:SLS) Trading Down 3.3%
Ticker Report Shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Get Free Report) traded down 3.3% during mid-day trading on Friday . The company traded as low as $1.16 and last traded at $1.19. 573,282...\n more…
SELLAS Life Sciences Group (NASDAQ:SLS) Posts Quarterly Earnings Results, Beats Estimates By $0.03 EPS
Ticker Report SELLAS Life Sciences Group (NASDAQ:SLS - Get Free Report) announced its quarterly earnings results on Tuesday. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of...\n more…
SLS Stock Earnings: SELLAS Life Sciences Gr Beats EPS for Q2 2024
InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips\nSLS stock results show that SELLAS Life Sciences Gr beat analyst estimates for earnings per share the second quarter of 2024.\nThe post...\n more…
SELLAS Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Globe Newswire - Announced Independent Data Monitoring Committee's (IDMC) Recommendation to Continue the Phase 3 REGAL Study in Patients with Acute Myeloid Leukemia (AML) Without Modifications: Interim Analysis...\n more…
SELLAS Life Sciences Group (NASDAQ:SLS) Stock Price Up 0.9%
Ticker Report SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Get Free Report)'s share price traded up 0.9% on Tuesday . The stock traded as high as $1.20 and last traded at $1.17. 928,643 shares were traded during...\n more…
SELLAS Receives EMA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas
Globe Newswire NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ( SELLAS or the Company ), a late-stage clinical biopharmaceutical company focused on the development of...\n more…